Pine Valley Investments Ltd Liability Co Purchases 9,217 Shares of Mesoblast Limited (NASDAQ:MESO)

Pine Valley Investments Ltd Liability Co boosted its position in Mesoblast Limited (NASDAQ:MESO) by 78.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 20,931 shares of the company’s stock after buying an additional 9,217 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Mesoblast were worth $414,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in MESO. GAMMA Investing LLC lifted its stake in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares during the last quarter. R Squared Ltd acquired a new position in shares of Mesoblast during the 4th quarter worth $30,000. Signaturefd LLC lifted its position in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Mesoblast in the fourth quarter valued at about $134,000. Finally, Sageworth Trust Co acquired a new stake in Mesoblast in the fourth quarter valued at about $198,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on the company. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler reissued an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Trading Down 2.2 %

Mesoblast stock opened at $15.70 on Thursday. The business has a 50 day moving average of $18.05 and a 200-day moving average of $12.01. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast Limited has a 1 year low of $1.91 and a 1 year high of $22.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.